Triamcinolone as Adjunctive Treatment to Laser Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

Abstract

To evaluate intravitreal injection of triamcinolone acetonide before laser panretinal photocoagulation (PRP) in the treatment of proliferative diabetic retinopathy.Methods: This interventional case series included 9 patients with bilateral proliferative diabetic retinopathy. One eye received intravitreal triamcinolone before PRP (injected eye) and the other, PRP alone (control eye). The main outcome measures were the change in planimetric area of fluorescein leakage from retinal neovascularization and in central macular thickness on optical coherence tomography at 3, 6, 9, and 12 months. Secondary end points were change in vision, intraocular pressure, and cataract progression.Results: All patients completed 9 months and 5 patients, 12 months of follow-up. Initial mean (SD) pla-

Triamcinolone and Bevacizumab as Adjunctive Therapies to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

“…In the present study, the thickness two months after PRP was similar to the baseline values. At 6 months after treatment, Bandello et al [9] reported a 17% increase in the macular thickness compared to baseline in patients who underwent PRP and focal laser treatment, which is in contrast to the results in the present study of 8.2% worsening after PRP alone.…”

“…BCVA remained stable in the different groups during the follow-up period, and no correlation with CMT was observed. These findings are similar to those reported for eyes that were treated with laser therapy alone [9, 29] and for eyes that were treated with bevacizumab [14, 19], but the results are poorer than those in eyes adjunctively treated with triamcinolone [9, 29, 31], as discussed above.…”

Triamcinolone and Bevacizumab as Adjunctive Therapies to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

“…In the present study, the thickness two months after PRP was similar to the baseline values. At 6 months after treatment, Bandello et al [9] reported a 17% increase in the macular thickness compared to baseline in patients who underwent PRP and focal laser treatment, which is in contrast to the results in the present study of 8.2% worsening after PRP alone.…”

“…BCVA remained stable in the different groups during the follow-up period, and no correlation with CMT was observed. These findings are similar to those reported for eyes that were treated with laser therapy alone [9, 29] and for eyes that were treated with bevacizumab [14, 19], but the results are poorer than those in eyes adjunctively treated with triamcinolone [9, 29, 31], as discussed above.…”

Intravitreal triamcinolone as adjunctive treatment to laser panretinal photocoagulation for concomitant proliferative diabetic retinopathy and clinically significant macular oedema

“…While the reduction in foveal thickness may have contributed to the improved VA, the extent of visual improvement did not correlate with the amount of reduction of foveal thickness; this finding is similar to those in other reports (Larsson et al. 2005; Bandello et al. 2006).…”

“…In our study, mean foveal thickness decreased from 559 µm to 436 µm, a greater improvement than that reported by Shimura et al. (2006) but not as much as the effect reported by Bandello et al. (2006).…”

Intravitreal Triamcinolone as an Adjunct to Standard Laser Therapy in Coexisting High-Risk Proliferative Diabetic Retinopathy and Clinically Significant Macular Edema

“…Also, vision slightly improved in injected eyes and worsened in control eyes indicating a beneficial adjuvant role of IVTA to PRP. 17 In line with the previous study, Kaise et al reported that the addition of IVTA to PRP in the treatment of eyes with high-risk PDR and CSME may prevent PRP-induced foveal thickening and loss of vision. 18 To our knowledge, there is no study assessing the beneficial effect of IVTA as an adjunct treatment to PRP and MPC in high-risk PDR with CSME eyes.…”

Triamcinolone and Bevacizumab as Adjunctive Therapies to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

“…In the present study, the thickness two months after PRP was similar to the baseline values. At 6 months after treatment, Bandello et al [9] reported a 17% increase in the macular thickness compared to baseline in patients who underwent PRP and focal laser treatment, which is in contrast to the results in the present study of 8.2% worsening after PRP alone.…”

“…BCVA remained stable in the different groups during the follow-up period, and no correlation with CMT was observed. These findings are similar to those reported for eyes that were treated with laser therapy alone [9, 29] and for eyes that were treated with bevacizumab [14, 19], but the results are poorer than those in eyes adjunctively treated with triamcinolone [9, 29, 31], as discussed above.…”

Intravitreal triamcinolone as adjunctive treatment to laser panretinal photocoagulation for concomitant proliferative diabetic retinopathy and clinically significant macular oedema

“…While the reduction in foveal thickness may have contributed to the improved VA, the extent of visual improvement did not correlate with the amount of reduction of foveal thickness; this finding is similar to those in other reports (Larsson et al. 2005; Bandello et al. 2006).…”

“…In our study, mean foveal thickness decreased from 559 µm to 436 µm, a greater improvement than that reported by Shimura et al. (2006) but not as much as the effect reported by Bandello et al. (2006).…”

Intravitreal Triamcinolone as an Adjunct to Standard Laser Therapy in Coexisting High-Risk Proliferative Diabetic Retinopathy and Clinically Significant Macular Edema

“…Also, vision slightly improved in injected eyes and worsened in control eyes indicating a beneficial adjuvant role of IVTA to PRP. 17 In line with the previous study, Kaise et al reported that the addition of IVTA to PRP in the treatment of eyes with high-risk PDR and CSME may prevent PRP-induced foveal thickening and loss of vision. 18 To our knowledge, there is no study assessing the beneficial effect of IVTA as an adjunct treatment to PRP and MPC in high-risk PDR with CSME eyes.…”

Triamcinolone and Bevacizumab as Adjunctive Therapies to Panretinal Photocoagulation for Proliferative Diabetic Retinopathy

“…In the present study, the thickness two months after PRP was similar to the baseline values. At 6 months after treatment, Bandello et al [9] reported a 17% increase in the macular thickness compared to baseline in patients who underwent PRP and focal laser treatment, which is in contrast to the results in the present study of 8.2% worsening after PRP alone.…”

“…BCVA remained stable in the different groups during the follow-up period, and no correlation with CMT was observed. These findings are similar to those reported for eyes that were treated with laser therapy alone [9, 29] and for eyes that were treated with bevacizumab [14, 19], but the results are poorer than those in eyes adjunctively treated with triamcinolone [9, 29, 31], as discussed above.…”

Intravitreal triamcinolone as adjunctive treatment to laser panretinal photocoagulation for concomitant proliferative diabetic retinopathy and clinically significant macular oedema

“…While the reduction in foveal thickness may have contributed to the improved VA, the extent of visual improvement did not correlate with the amount of reduction of foveal thickness; this finding is similar to those in other reports (Larsson et al. 2005; Bandello et al. 2006).…”

“…In our study, mean foveal thickness decreased from 559 µm to 436 µm, a greater improvement than that reported by Shimura et al. (2006) but not as much as the effect reported by Bandello et al. (2006).…”

Intravitreal Triamcinolone as an Adjunct to Standard Laser Therapy in Coexisting High-Risk Proliferative Diabetic Retinopathy and Clinically Significant Macular Edema

“…Also, vision slightly improved in injected eyes and worsened in control eyes indicating a beneficial adjuvant role of IVTA to PRP. 17 In line with the previous study, Kaise et al reported that the addition of IVTA to PRP in the treatment of eyes with high-risk PDR and CSME may prevent PRP-induced foveal thickening and loss of vision. 18 To our knowledge, there is no study assessing the beneficial effect of IVTA as an adjunct treatment to PRP and MPC in high-risk PDR with CSME eyes.…”